Synlogic, Inc. (SYBX)
NASDAQ: SYBX · Real-Time Price · USD
1.660
-0.030 (-1.78%)
At close: Oct 3, 2025, 4:00 PM EDT
1.700
+0.040 (2.41%)
After-hours: Oct 3, 2025, 4:33 PM EDT

Company Description

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.

Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.

Synlogic, Inc.
Synlogic logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees1
CEOMary Dooley

Contact Details

Address:
PO Box 30
Winchester, Massachusetts 01890
United States
Phone617 659 2802
Websitesynlogictx.com

Stock Details

Ticker SymbolSYBX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001527599
CUSIP Number87166L100
ISIN NumberUS87166L2097
Employer ID26-1824804
SIC Code2834

Key Executives

NamePosition
Mary Beth DooleyPrincipal Executive Officer and Principal Financial Officer
Dr. Timothy K. Lu M.D., Ph.D.Co-Founder and Member of Scientific Advisory Board
Dr. James J. Collins Ph.D.Co-Founder and Member of Scientific Advisory Board
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.Advisor

Latest SEC Filings

DateTypeTitle
Aug 20, 2025EFFECTNotice of Effectiveness
Aug 15, 2025S-3/A[Amend] Registration statement under Securities Act of 1933
Aug 13, 2025UPLOADFiling
Aug 8, 2025S-3Registration statement under Securities Act of 1933
Aug 7, 202510-QQuarterly Report
May 8, 202510-QQuarterly Report
Apr 30, 202510-K/A[Amend] Annual report
Mar 6, 202510-KAnnual Report
Feb 25, 2025SCHEDULE 13G/AFiling
Feb 21, 20258-KCurrent Report